ClinicalTrials.gg
CompletedNCT03945604Updated Aug 12, 2022

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

A Phase 1 interventional study of SHR-1210 + Apatinib +Fluzoparib in Triple Negative Breast Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-12.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing camrelizumab in Triple Negative Breast Neoplasms — 11 open to participants now, 12 under way, 4 of them phase 3. camrelizumab · Triple Negative Breast Neoplasms.

Enrollment
16th of 21
32 · median 90
Started
2019
with 1 other
Phase 1
Only one
of the 21
Registered
2nd of 21
by date
Lead sponsor
3 of 21
Jiangsu HengRui Medicine Co., Ltd.

Among the 21 studies testing camrelizumab in Triple Negative Breast Neoplasms, this one is the 16th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 1, and was the 2nd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

11 of the 21 studies testing camrelizumab in Triple Negative Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing camrelizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the tolerability, safety and efficacy of SHR-1210 in combination with Apatinib and Fluzoparib in subjects with recurrent and metastatic triple negative breast cancer

Read the detailed description

Drug: SHR-1210 + Apatinib +Fluzoparib SHR-1210 will be administered as an intravenous infusion, Apatinib tablets will be given orally, Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.

Treatment group : PD-1 antibody SHR-1210 combination with apatinib and fluzoparib

03

Conditions studied

  • Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed the .
  • Female aged ≥18 years old.
  • diagnosed patients with recurrent and triple negative breast cancer.
  • No more than 2-line chemotherapy failed at the stage of recurrence and metastasis .
  • Patients who have been treated with platinum-based regimen at the stage of recurrence/metastasis need non-disease progression (non-pd)during treatment
  • At least one measuring lesion that confirmed by v1.1 standard.
  • The patients can swallow pills.
  • Have a of at least 12 weeks.
  • The functions of vital organs meet protocal requirements.

Exclusion criteria

Exclusion Criteria:

  • Subjects had any history of active disease .
  • Subjects had previously been treated with and PD-L1 antibodies, or was known to be allergic to antibody drugs, or had previously been treated with apatinib, or had previously been treated with PARP inhibitors.
  • Subjects have untreated central nervous system .
  • History of hypertension and antihypertensive medications are not well controlled.
  • Some clinical symptoms or diseases of the heart that are not well controlled.
  • History of immunodeficiency including -positive.
  • Subjects had active infections.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    SHR-1210 + Apatinib +Fluzoparib

    SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity

    Drug: SHR-1210 + Apatinib +Fluzoparib

Interventions

  • DrugSHR-1210 + Apatinib +Fluzoparib

    Drug pages: Camrelizumab · Apatinib · Fluzoparib

    SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.

    Also known as: Treatment group : PD-1 antibody SHR-1210 combination with apatinib and fluzoparib

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    Dose Limiting Toxicity

    Time frame: First cycle (28 days)

Secondary outcomes

  1. Adverse Events and Serious Adverse Events

    AEs and SAEs

    Time frame: from the first drug administration to within 90 days for the last SHR-1210 dose

  2. Overall Response Rate (ORR)

    Time frame: up to 12 months (approx) from the start of treatment

  3. Duration of response (DoR)

    Time frame: up to 12 months (approx) from the start of treatment

  4. Disease Control Rate

    DCR

    Time frame: up to 12 months (approx) from the start of treatment

  5. Progression-Free-Survival

    PFS

    Time frame: up to 12 months (approx) from the start of treatment

  6. 12-months overall survival rate

    12-months overall survival rate

    Time frame: From the start of treatment to 1 year

07

Study locations

1 site
  • Beijing Cancer Hosptial
    Beijing, Beijing 100142, China
08

References and documents

Publications

  • Zhang Q, Shao B, Tong Z, Ouyang Q, Wang Y, Xu G, Li S, Li H. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. BMC Med. 2022 Oct 3;20(1):321. doi: 10.1186/s12916-022-02527-6. PubMed 36184642 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Feb 2021, 20 months.

Of 136 industry-sponsored phase 1 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 70. This study's 20 months is below that.

Counting every sponsor, half of 209 studies reached it within 54 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2019
First posted
May 10, 2019
StartActual
Jun 4, 2019
Primary completionActual
Feb 9, 2021
CompletionActual
Feb 9, 2021
Last update
Aug 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03945604
Responsible party
Sponsor
First posted
May 10, 2019
Start date
Jun 4, 2019
Primary completion
Feb 9, 2021
Completion
Feb 9, 2021
Last update
Aug 12, 2022

Study contacts

Huiping Li, PhD
principal investigator · Beijing Cancer Hosptial

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Apatinib · Fluzoparib

Start the discussion